KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS
We are a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. We have developed and are commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest ("SCA") during vulnerable periods of recovery.
Our Cardiac Recovery System platform is anchored by the ASSURE® Wearable Cardioverter Defibrillator ("WCD"), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $95.1M | $59.8M | $27.8M | — |
| Cost of revenue | $46.3M | $35.6M | $27.5M | — |
| Gross profit | $48.9M | $24.2M | $362.0K | — |
| R&D | $19.5M | $15.7M | $15.5M | — |
| SG&A | $164.1M | $114.9M | $69.9M | — |
| Total operating expenses | $183.6M | $130.6M | $85.4M | — |
| Operating income | -$134.7M | -$106.4M | -$85.1M | — |
| Interest expense | $7.5M | $7.7M | $6.2M | — |
| Pre-tax income | -$131.3M | -$113.7M | -$94.1M | — |
| Income tax | $294.0K | $135.0K | $24.0K | — |
| Net income | -$131.6M | -$113.8M | -$94.1M | — |
| EPS, basic | -2.43 | -5.13 | -5.07 | — |
| EPS, diluted | -2.43 | -5.13 | -5.07 | — |
| Shares, diluted (wtd. avg.) | 54.2M | 24.6M | 19.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $99.7M | $237.6M | $8.6M | $15.3M |
| Short-term investments | $96.7M | — | — | — |
| Receivables | $14.5M | $8.1M | $2.0M | — |
| Total current assets | $222.4M | $255.3M | $14.9M | — |
| Property, plant and equipment | $59.1M | $34.8M | $26.1M | — |
| Total assets | $358.5M | $295.7M | $45.9M | — |
| Accounts payable | $27.3M | $24.0M | $23.9M | — |
| Total current liabilities | $50.4M | $38.0M | $33.0M | — |
| Long-term debt | $42.6M | $41.1M | $42.5M | — |
| Total liabilities | $98.8M | $90.3M | $78.2M | — |
| Retained earnings | -$651.9M | -$520.2M | -$406.4M | — |
| Total equity | $259.7M | $205.4M | -$209.4M | -$117.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$81.7M | -$77.6M | -$72.2M | — |
| Depreciation and amortisation | $8.7M | $8.0M | $11.6M | — |
| Stock-based compensation | $33.6M | $24.3M | $1.5M | — |
| Capital expenditure | $34.9M | $22.9M | $12.2M | — |
| Investing cash flow | -$203.3M | -$23.3M | -$12.2M | — |
| Financing cash flow | $147.1M | $330.3M | $77.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-303397.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $27.8M | $59.8M | $95.1M |
| Gross profit | — | $362.0K | $24.2M | $48.9M |
| Net income | — | -$94.1M | -$113.8M | -$131.6M |
Recent filings and events
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Results announced Item 2.02
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |